GS-441524 for COVID-19 SAD, FE, and MAD Study in Healthy Subjects
Status:
WITHDRAWN
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of GS-441524 in healthy subjects. The main questions to answer are: 1) What dosage of GS-441524 is required for adequate therapeutic plasma levels? 2) Does fed or fasted state produce variability in plasma levels? 3) How is GS-441524 eliminated from the body.
Participants will receive varying levels of GS-441524 or placebo to evaluate AEs and plasma levels.
Phase:
PHASE1
Details
Lead Sponsor:
National Center for Advancing Translational Sciences (NCATS)
Collaborators:
ICON Government and Public Health Solutions, Inc Leidos Biomedical Research, Inc.